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Background: Studies of the lung function profiles of exclusive narghile smokers (ENS) are few, have some
methodological limits, and present contradictory conclusions. The present study aimed to compare the
plethysmographic profiles of ENS with age- and height-matched exclusive cigarette smokers (ECS).
Methods: Males aged 3560 living in Sousse, Tunisia, who have been smoking narghile exclusively for more
than 10 narghile-years (n36) or cigarettes exclusively for more than 10 pack-years (n106) were recruited
to participate in this casecontrol study. The anthropometric and plethysmographic data were measured
according to international recommendations using a body plethysmograph (ZAN 500 Body II, Mebgreräte
GmbH, Germany). Large-airway-obstructive-ventilatory-defect (LAOVD) was defined as: first second forced
expiratory volume/forced vital capacity (FEV1/FVC) below the lower-limit-of-normal (LLN). Restrictive-
ventilatory-defect (RVD) was defined as total lung capacityBLLN. Lung hyperinflation was defined as
residual volumeupper-limit-of-normal. Student t-test and x2 test were used to compare plethysmographic
data and profiles of the two groups.
Results: The subjects in the ENS and ECS groups are well matched in age (4597 vs. 4795 years) and height
(1.7390.06 vs. 1.7290.06 m) and used similar quantities of tobacco (36922 narghile-years vs. 35919 pack-
years). Compared to the ENS group, the ECS group had significantly lower FEV1 (84912 vs. 60921%), FVC
(90912 vs. 76918%), and FEV1/FVC (9997 vs. 83917%). The two groups had similar percentages of RVD
(31 vs. 36%), while the ECS group had a significantly higher percentage of LAOVD (8 vs. 58%) and lung
hyperinflation (36 vs.57%).
Conclusion: Chronic exclusive narghile smoking has less adverse effects on pulmonary function tests than
chronic exclusive cigarette smoking.
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T
he past decade has seen a global increase in
narghile tobacco consumption at a remarkable
pace (14). The World Health Organization has
stressed that ‘the narghile is not only a health risk, but is
also a gateway to smoking for a number of young people’
(5) and the American Lung Association has described it
as an ‘emerging deadly trend’ (6).
The damaging effects of narghile smoking are not well
investigated (2, 79). To the best of our knowledge,
studies of the lung function of exclusive narghile smokers
(ENS) are few (1019). These studies evaluating the
chronic effects of narghile use on lung function present
contradictory conclusions: lack of ventilatory defects (13,
14, 17), minimal (11) to significant (15, 16, 18) small-
airways-obstructive-ventilatory-defect (SAOVD), large-
airways-obstructive-ventilatory-defect (LAOVD) (10, 12,
15, 16, 18), restrictive-ventilatory-defect (RVD) (18), high
frequency of lung hyperinflation (18), and acceleration of
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lung ageing with a significantly higher estimated-lung-
age (ELA) when compared to chronological-lung-age
(CLA) (18).
The majority of these studies (1018) used limited
methodology such as low sample sizes (12, 14, 17) or
inclusion of mixed cigarette and narghile smokers (10) or
inclusion of elderly subjects aged more than 60, who
probably suffer from co-morbidities that could influence
lung function (11, 15). In addition, some studies measured
only expiratory flows (1017) and not lung volumes.
Furthermore, there is a lack of comparison with exclusive
cigarette smokers (ECS) or healthy non-smokers (18).
A recent meta-analysis (7), which included only six
studies (1016), showed no differences in first second
forced expiratory volume (FEV1) and in FEV1/forced
vital capacity (FVC) between narghile and cigarette
smokers. The present study aimed to compare the
plethysmographic parameters, measured according to
recent lung function testing guidelines (20, 21), of ENS
with age- and height-matched ECS. The null hypothesis is




This was a casecontrol study spread over 1 year (from
February 2010 to January 2011). It was conducted in the
Department of Physiology and Functional Explorations
at the Farhat Hached Hospital in Sousse, Tunisia. The
city lies on the Gulf of Hammamet on the Mediterranean
Sea and has 173,047 inhabitants (year 2010). In unpub-
lished data, the adjusted prevalence rates of smoking
among males aged 2093 living in Sousse were 40.1% for
cigarette and 12.7% for narghile.
The study was conducted in accordance with the
Declaration of Helsinki. Participants provided written
consent and the study protocol was approved by the
ethics committee of the hospital (approval number 2211/
2009).
Sample size
The null hypothesis (22) was H0: m1m2 and the
alternative hypothesis was Ha: m1m2d, where d is
the difference between two means and n1 and n2 are the
sample sizes for the ENS and ECS groups, such Nn1
n2. The total sample size was estimated using the formula
(22) N [(r1)(Za/2Z1-b)
2 s2]/r d2. Za is the normal
deviate at a level of significance1.96 (5% level of
significance), Z1-b is the normal deviate at 1-b% power
with b% of type II error (0.84 at 80% statistical power); ‘r’
equal to n1/n2 is the ratio of sample size required for two
groups (r0.33 gives the sample size distribution as
1:3 for two groups). ‘r’ was considered because of the
unequal sample sizes due to various reasons, such as
higher prevalence of cigarette smokers compared to
narghile smokers (of 13,776 smokers consulting a non-
governmental organization (23), 34 and 11% were ECS
and ENS, respectively). s and d are the pooled standard
deviation (SD) and difference of FEV1 means of two
groups. These two values were obtained from a previous
study based on a similar hypothesis (14) in which the
researchers found that the mean FEV1 (L) in two groups
was 3.2 and 3.6 and common SD was 0.85. The total
sample size for the study was 142 subjects (36 ENS and
106 ECS).
Population
Subjects were selected by convenience sampling from the
staff of the local Faculty of Medicine and/or hospital, as
well as from acquaintances of people involved in the
study. Volunteers were not controlled for socioeconomic
differences or ethnicity.
Only males aged 3560 without a history of asthma,
allergies, pulmonary tuberculosis, or recent respiratory
tract infection were included. Other exclusion criteria
included co-morbidities other than those related to
tobacco use (e.g. cardiovascular diseases, diabetes, and
neoplasia) and imperfect performance of the respiratory
maneuvers. Only smokers of more than 10 narghile-years
(NY, e.g. one NY for one narghile a day for 1 year) and
more than 10 pack-years (PY, e.g. one PY for one pack a
day for 1 year) were included in ENS and ECS groups, res-
pectively. The ECS and ENS must have stopped smoking at
least for 2 h (17, 24) and 1 day (12, 13), respectively. The
type of used narghile tobacco was tabamel.
Collected data, tobacco use evaluation, and physical
examination
The following data were collected: narghile use, cigarette
consumption, anthropometry [CLA, weight, height, body
mass index (BMI)] and plethysmographic data [FVC,
FEV1, FEV1/FVC, thoracic gas volume (TGV), residual
volume (RV), total lung capacity (TLC)], and ELA.
Datawere collected using a questionnaire recommended
for epidemiological studies (25). Narghile use and cigarette
consumption were self-reported. Height (90.01 m) was
measured with a height gauge (standing stadiometer type
DETECTO†) with shoes removed, heels joined, and back
straight. Weight (91 kg) was measured with a digital scale
(OHAUS, Florhman Park, NJ, USA) and BMI (weight/
height2) was calculated. Depending on BMI, the partici-
pants were classified as follows (26): underweight (BMIB
18.5), normal weight (18.55BMIB25), overweight (255
BMIB30), and obese (BMI]30).
Plethysmographic measurements
Plethysmographic measurements were performed by MK,
SN, and MBE following the American Thoracic Society
and the European Respiratory Society (ATS/ERS)
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recommendations (20, 21). They were performed with a
body plethysmograph (daily calibration) (ZAN 500 Body
II, Mebgreräte GmbH, Germany).
The plethysmography procedure was explained to the
participants and performed without potential harm. The
plethysmograph door was closed and time was allotted
for thermal transients to stabilize and for patients to
relax. Subjects were then instructed to attach the mouth-
piece and breathe quietly until they achieved stable end-
expiration. When subjects were at or near TGV, the
shutter was closed at end-expiration for 23 sec, and
they were instructed to perform a series of gentle pants
(91 kPa) at a frequency of 0.51.0 Hz. A series of 35
technically satisfactory panting maneuvers was recorded,
the shutter was opened and subjects performed an
expiratory reserve volume maneuver followed by a slow
inspiratory vital capacity maneuver. At least three
plethysmographic TGV values that agreed within 5%
were obtained and the mean value was recorded.
The FVC maneuver had three distinct phases (20):
maximal inspiration, a blast of exhalation and continued
complete exhalation to the end of testing. Subjects were
verbally encouraged to continue exhaling air at the end of
the maneuver to obtain optimal effort. The criterion for
end of testing was a volumetime curve showing no
change in volume (0.025 L) for 1 sec, despite the patient’s
effort to exhale for at least 6 sec. Repeatability was
acceptable when the difference between the largest and
the next largest FVC was 50.150 L and 3%, and the
difference between the largest and next largest FEV1 was
50.150 L and 3%. Plethysmographic data were expressed
in absolute values and as a percent of reference values
derived from local spirometric norms (27).
Spirometric definitions were based on the recent in-
ternational recommendations (20) and therefore the
application of lower-limit-of-normal (LLN) and upper-
limit-of-normal (ULN) (20). LAOVD was defined as
a ‘FEV1/FVCBLLN’, RVD as ‘TLCBLLN’, mixed-
ventilatory-defect (MVD) as the association of a ‘TLC
BLLN’ and a ‘FEV1/FVCBLLN’, lung hyperinflation
as ‘RVULN’ (28) and non-specific-ventilatory-defect
(NSVD) as a decrease (BLLN) in FVC and/or FEV1
with normal FEV1/FVC and TLC (20). ELA was
calculated (29).
Statistical analysis
Variables distributions were normal and results were
expressed as mean9SD.
A student’s t-test was used to compare means of
anthropometric and plethysmographic values.
A non-parametric test (Wilcoxon matched pairs test)
was used to compare ELA with CLA of each group.
x2 test was used to compare the profiles of the two
groups.
All mathematical computations and statistical proce-
dures were performed using Statistica software (Statistica
Kernel version 6; Stat Software. France). Significance was
set at the 0.05 level.
Results
Anthropometric data, obesity status, and tobacco
use
Compared to ENS group, the ECS one includes low
percentage of subjects aged 3545 (25.0 vs. 5.0%,
respectively) (Fig. 1).
There were no statistically significant differences be-
tween the two groups’ ages and heights (Table 1). In
addition, the means of the amounts of tobacco used were
similar for the two groups (36922 NY vs. 35919 PY, p
0.88). The ENS group had a significantly higher weight
and BMI than the ECS group (Table 1). This reflects a
tendency toward obesity as evidenced by a significantly
higher percentage of obesity status in the ENS group
compared to the ECS one (44.4 vs. 20.7%, respectively).
Plethysmographic parameters
The ECS group had a more pronounced tendency to an
obstructive defect, with a significantly lower FEV1, FVC,
and FEV1/FVC (Table 1). However, no statistically
significant difference in lung volume was found between
the two groups.
Narghile and cigarette smoking accelerate the aging of
lung function, but this was significantly greater in the
ECS group (‘ELA minus CLA’ was 42932 vs. 18923
years; p0.001).
Plethysmographic profiles
The percentages of subjects with plethysmographic read-
ings outside the normal range or having ventilatory
defects are shown in Table 2. The ENS group had
Fig. 1. Age distribution of participants.
ENS, exclusive narghile smokers; ECS, exclusive cigarette
smokers. apB0.05 (x2 test): ENS vs. ECS.
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significantly lower percentages of subjects with reduced
FEV1 or FVC, with LAOVD, or lung hyperinflation.
Percentages of subjects with RVD, MVD, or NSVD were
similar in the two groups.
Discussion
We compared two age- and height-matched groups: 36
ENS of more than 10 NY and 106 ECS of more than 10
PY. The ECS group had significantly lower FEV1, FVC,
and FEV1/FVC, and significantly higher percentages of
subjects with LAOVD or with lung hyperinflation. The
two groups had similar percentages of subjects with RVD,
MVD, or NSVD. Therefore, the null hypothesis, that
there is no difference between the plethysmographic data
of the two groups, is rejected. Both narghile and cigarette
smoking accelerate the aging of lung function, but our
study shows that cigarettes have a more detrimental
effect.
The harmful effects of narghile use on lung function
highlighted in the present study are part of a more
general phenomenon (2). Studies analyzing ENS lung
function are rare, have several methodological limits, and
have yielded conflicting results (1, 2, 7, 18) (Supplemen-
tary file). A systematic review and meta-analysis of the
chronic effects of narghile use on lung function (7) found
no studies on the association of narghile smoking with
airways diseases in general, and with chronic obstructive
pulmonary disease (COPD) in particular.
Comparison of plethysmographic data
Cigarette smoking could be more harmful to airways
than narghile smoking (11). We found that FEV1, FVC
and FEV1/FVC were significantly lower among ECS than
ENS (Table 1). Our results are in agreement with other
studies (FEV1 (10, 11), FVC (10), FEV1/FVC (10, 11))
but at odds with others reporting no significant dif-
ferences (FEV1 (13), FVC (11, 13), FEV1/FVC (13)).
Noteworthy, gender could influence comparisons (10).
Al-Fayez et al. (10) reported that among females, FEV1
and FVC were not significantly lower among ECS than
ENS. In their systematic review and meta-analysis, Raad
Table 1. Subjects’ characteristics: exclusive narghile smokers (ENS, n36) and exclusive cigarette smokers (ECS, n106)
ENS ECS % difference
Anthropometric and spirometric data (data are mean9SD)
Chronological-lung-age (CLA) (yr) 4597 4795 4.44
Estimated-lung-age (ELA) (yr) 63923# 89934# 41.27*
Height (m) 1.7390.06 1.7290.06 0.58
Weight (kg) 88913 74917 15.91*
Body mass index (kg/m2) 2994 2595 13.79*
FEV1 (L) 3.3990.58 2.4190.88 28.91*
FEV1 (% pred) 84912 60921 28.57*
FVC (L) 4.2490.69 3.5490.94 16.51*
FVC (% pred) 90912 76918 15.56*
FEV1/FVC (absolute value) 0.8090.06 0.6790.14 16.25*
FEV1/FVC (% pred) 9997 83917 16.16*
TGV (L) 3.9392.16 4.3591.53 10.69
TGV (% pred) 110960 120942 9.09
RV (L) 2.8991.97 3.2791.68 13.15
RV (% pred) 136997 159982 16.91
TLC (L) 7.1792.21 7.0091.93 2.37
TLC (% pred) 98930 97926 1.02
Obesity status (data are number; percentage)
Underweight 0 (0.00%) 7 (6.60%)
Normal weight 3 (8.33%) 51 (48.11%)$
Overweight 17 (47.22%) 26 (24.53%)$
Obesity 16 (44.44%) 22 (20.75%)$
FEV1, first second forced expiratory volume; FVC, forced vital capacity; RV, residual volume; TGV, thoracic gas volume; TLC, total lung
capacity; Pred, predicted.
% difference(ENS  ECS)/ENS.
*pB0.05 (t-test): ENS vs. ECS.
#pB0.05 (Wilcoxon test): ‘CLA’ vs. ‘ELA’ for the same group.
$pB0.05 (x2 test): ENS vs. ESC.
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et al. (7) concluded that the overall quality of evidence for
FEV1 was moderate for ENS and low for ECS.
Only one study measured ENS lung volume (18). It
found significant increases, in comparison with local
norms, of the RV and functional residual capacity (FRC),
and in the RV/TLC and FRC/TLC ratios (18). We
confirm the previous data, and the increase in lung
volume indicates a trend toward lung hyperinflation
(Table 1). To the best of our knowledge, the present
study is the first to compare ENS lung volumes with
those of an ECS.
Plethysmographic profiles
Eight percent of ENS had LAOVD and thus probably
presented COPD. This percentage, close to that found by
some authors (4% (11), 6% (18)), supports the idea that
COPD post-narghile is more rare than post-cigarettes
(11, 15, 18). This finding is contrary to other findings (30)
suggesting a possible role of narghile smoking in the
development of COPD (7). Indeed, we found that 58%
of ECS of more than 10 PA had LAOVD. The high
frequency of LAOVD among our ECS is similar to that
found in a previous study on 121 ECS, of which 56% had
LAOVD.
We identified RVD in 36 and 31% of ENS and ECS,
respectively. A previous study found RVD in 14% of ENS
of more than one NY (18). The restrictive pattern cannot
be explained by the inclusion in the present study of obese
subjects. Indeed, impaired respiratory function only
appears in cases of severe obesity without any proven
pulmonary disease (31). Moreover, in the ENS group,
only three subjects presented severe obesity with an
average BMI of 3792 kg/m2. Thus, RVD could be
explained by the particular composition of narghile
smoke, which is rich in heavy metals such as lead, arsenic,
and nickel (32), known as risk factors for developing
fibrosis and/or pneumoconiosis (33).
We observed lung hyperinflation in 36% of ENS, which
was significantly lower than observed in ECS (57%) but
resembles that previously found in ENS of more than one
NY (36%) (18). To the best of our knowledge, no other
author has shown that narghile use is responsible for
these types of defects. However, radiological studies are
desirable.
Estimated lung-age
One of the major results of this study was that narghile
use accelerates lung ageing. It was previously found
that the ELA of ENS was significantly higher than
CLA (47918 vs. 34910 years) (18). However, contrary to
a previous report (10) describing ENS as being at greater
risk than ECS for decreased pulmonary function, we
show that aging is significantly greater among ECS. Our
results can be used to encourage smoking cessation (34).
How can the harmful effects of narghile use on lung
function be explained?
This question was previously asked and several hypoth-
eses were advanced (2, 18). As in ECS (35), the answer to
this question requires the study of bronchial biopsies,
induced sputum samples and bronchoalveolar-lavage
fluid. These explorations are rarely performed on ENS.
Recently, Nemmar et al. (36) assessed the chronic
respiratory effects in mice of nose-only exposure (session
of 30 min/day, 5 days/week for 1 month) to mainstream
narghile smoke generated by commercially available
tabamel tobacco. An increase in neutrophil and lympho-
cyte numbers was observed, and airway resistance was
Table 2. Comparison of the plethysmographic profiles of exclusive narghile smokers (ENS, n36) and exclusive cigarette
smokers (ECS, n106)
ENS ECS
Plethysmographic values lower than the lower-limit-of-normal
Forced vital capacity (FVC) 10 (28) 55 (52)*
First second forced expiratory volume (FEV1) 17 (47) 93 (88)*
FEV1/FVC 3 (8) 61 (58)*
Total lung capacity 13 (36) 63 (31)
Plethysmographic values higher than the upper-lower-of-normal
Thoracic gas volume 13 (36) 42 (40)
Residual volume 13 (36) 60 (57)*
Total lung capacity 13 (19) 11 (10)
Other ventilatory defects
Mixed-ventilatory-defect 1 (3) 10 (9)
Non-specific-ventilatory-defect 7 (19) 14 (13)
Data are numbers (percentage).
*pB0.05 (x2 test): ENS vs. ESC.
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significantly increased in response to narghile smoke.
Moreover, tumor necrosis factor a and interleukin 6
concentrations were significantly increased in bronchoal-
veolar-lavage fluid, lipid peroxidation in lung tissue
significantly increased, and the level and activity of
antioxidants significantly decreased. This indicates the
occurrence of oxidative stress. Moreover, carboxyhemo-
globin levels were significantly increased. The authors
concluded that 1-month nose-only exposure to narghile
smoke significantly increased airway resistance, inflam-
mation and oxidative stress. This study (36) provides a
mechanistic explanation for the detrimental chronic respi-
ratory effects of narghile smoking. Other hypothetical
explanations (Supplementary file) can be advanced (2).
Why narghile smoking does not affect pulmonary
functions as seriously as cigarette smoking?
There are some hypotheses, advanced by Kiter et al. (11),
on this issue that still need further investigation. Due to
the relatively long periods of time between narghile
smoking sessions in comparison to cigarette smoking,
narghile use allows healing of small airways inflamma-
tion. Due to the rapid and short smoking pattern,
narghile smoke does not reach the peripheral airways,
and the filtration of smoke in the water may play the
most important role in decreasing the harmful effects
(11). Carbon monoxide (CO), nicotine, and tar, the most
harmful contents of tobacco smoke, are filterable. How-
ever, recent evidence has shown that water does not
significantly filter out the nicotinic products in narghile
smoke (37).
Highlights of studies on the chronic effects of narghile
smoking on lung function are presented in the Supple-
mentary file. Only some studies (13, 15, 16, 18) used
standardized medical questionnaires. There is an urgent
need to standardize items in epidemiological question-
naires used in studies on narghile use (38). The present
study applied non-inclusion criteria, discussed in the
Supplementary file, are in line with these reported for
such studies (1019). The present study high percentage
of obese ENS (two times more than ECS) is similar to
that reported by Shafique et al. (39) (i.e. compared to
healthy non-smokers, ENS were significantly more likely
to have obesity; odds ratio1.93). In addition, the
deterioration in lung function associated with obesity
appears only in the case of severe obesity without any
proven pulmonary disease (31). In the present study, only
6% of the ENS presented severe obesity; they were not
excluded. Other factors not assessed in our study, such as
occupational exposure, environmental pollutants, socio-
economic factors, or diet, might have influenced the
results. However, when answering the medical question-
naire, no ENS reported being followed by an occupa-
tional physician. The calculated sample size (n142) is
satisfactory (22). It is larger than those used in some
studies (12, 14, 17) but smaller than in others (10, 11, 13,
15, 16, 18). Unlike most other studies, we measured static
lung volumes, which are essential to diagnosis RVD (20)
and lung hyperinflation (40). Contrary to most published
studies, which used old spirometric recommendations and
definitions, we applied recent international definitions
(20) based on the use of LLN and ULN notions. In
addition, unlike two other studies (11, 15) that applied
Caucasian norms, we used Tunisian spirometric reference
values (27). The application of inappropriate norms leads
to misinterpretation of spirometry data in a substantial
proportion of subjects, which could result in an inaccu-
rate diagnosis (41). It is important to note that some
studies used neither spirometric guidelines (10, 12, 17)
nor spirometric norms (10, 1214, 16, 17).
Study limitations
Convenience sampling is a statistical method of drawing
representative data by selecting people because of the ease
of their volunteering. Its advantages are the availability
and the quickness with which data can be gathered. Its
disadvantages are the risk that the sample might not
represent the population as a whole, and it might be
biased by volunteers.
Smoking cessation of 1 day for narghile and 2 h does
not seem to affect the results. In fact, according the ERS/
ATS (42), smoking within at least 1 h of testing is an
activity that should preferably be avoided prior to lung
function testing. In addition, the first changes associated
with smoking are in the small airways (43) and so the
duration since the last smoking affects only the preva-
lence of SAOVD.
In this study, we analyzed the chronic effects of
exclusive narghile use on respiratory impairment using
plethysmographic markers. However, there are other
markers, such as CO in expired air or carboxyhemoglo-
bin, the study of respiratory mucociliary clearance half-
life, the percentage of retention of radioactivity at the end
of the first hour, or penetration index (12, 14, 44, 45).
Completion of the evaluation with a bronchial reversi-
bility test (46) and/or measurement of diffusing capacity
for CO (47) would also have been useful. Similarly, it
would have been useful to perform, as part of disability
and handicap evaluation, a walk test and a quality of life
questionnaire (48). In this study, we focused only on the
purely functional aspects of exclusive narghile use.
However, ENS may complain of some clinical signs,
such as dyspnea, wheezing, or respiratory illness (8, 13,
15, 16).
In conclusion, chronic exclusive narghile smoking is
less detrimental to pulmonary function than chronic
exclusive cigarette smoking.
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